Citadel Advisors
CAPR icon

Citadel Advisors’s Capricor Therapeutics CAPR Stock Holding History

Citadel Advisors’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.22M Sell
258,400
-78,100
-23% -$2.37M ﹤0.01% 4350
2026
Q1 		$10.2M Sell
336,500
-153,500
-31% -$4.09M ﹤0.01% 3224
2025
Q4 		$14.1M Sell
490,000
-255,600
-34% -$3.34M ﹤0.01% 2780
2025
Q3 		$5.38M Buy
745,600
+443,600
+147% +$3.27M ﹤0.01% 4232
2025
Q2 		$3M Buy
302,000
+38,400
+15% +$406K ﹤0.01% 4979
2025
Q1 		$2.5M Sell
263,600
-58,800
-18% -$816K ﹤0.01% 5111
2024
Q4 		$4.45M Buy
322,400
+238,500
+284% +$4.18M ﹤0.01% 4145
2024
Q3 		$1.28M Buy
83,900
+46,800
+126% +$231K ﹤0.01% 6365
2024
Q2 		$177K Buy
37,100
+16,200
+78% +$90.3K ﹤0.01% 10102
2024
Q1 		$142K Sell
20,900
-3,500
-14% -$16.9K ﹤0.01% 10846
2023
Q4 		$119K Buy
24,400
+3,000
+14% +$9.77K ﹤0.01% 10704
2023
Q3 		$73.2K Buy
21,400
+17,900
+511% +$101K ﹤0.01% 11276
2023
Q2 		$16.7K Sell
3,500
-41,300
-92% -$181K ﹤0.01% 12882
2023
Q1 		$189K Sell
44,800
-39,800
-47% -$171K ﹤0.01% 10278
2022
Q4 		$327K Buy
84,600
+4,700
+6% +$22.4K ﹤0.01% 9130
2022
Q3 		$479K Sell
79,900
-35,300
-31% -$181K ﹤0.01% 8543
2022
Q2 		$402K Buy
115,200
+29,500
+34% +$105K ﹤0.01% 9130
2022
Q1 		$294K Sell
85,700
-15,900
-16% -$62.7K ﹤0.01% 10636
2021
Q4 		$298K Sell
101,600
-41,800
-29% -$146K ﹤0.01% 10937
2021
Q3 		$576K Buy
143,400
+45,300
+46% +$206K ﹤0.01% 9531
2021
Q2 		$503K Buy
98,100
+48,700
+99% +$206K ﹤0.01% 10049
2021
Q1 		$231K Sell
49,400
-15,400
-24% -$88.7K ﹤0.01% 11425
2020
Q4 		$222K Buy
64,800
+32,200
+99% +$140K ﹤0.01% 9577
2020
Q3 		$171K Buy
+32,600
New +$190K ﹤0.01% 8926

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors's CAPR Position: Q2 2026 in Review

Citadel Advisors increased its Capricor Therapeutics (CAPR) stake by 51% in Q2 2026, buying an estimated $8.34M and bringing the position to 814,444 shares worth $19.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2615.

Citadel Advisors first reported a position in CAPR in Q3 2016 and has held it in 29 quarters since. The position peaked at $26M in Q4 2025. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Citadel Advisors held 814,444 shares of Capricor Therapeutics worth $19.6M as of Q2 2026.
  • Citadel Advisors bought 275,212 Capricor Therapeutics shares in Q2 2026, an estimated $8.34M.
  • Capricor Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2615 holding.
  • Citadel Advisors first reported a position in Capricor Therapeutics in Q3 2016 and has held it in 29 quarters since.
  • Citadel Advisors's Capricor Therapeutics position peaked at $26M in Q4 2025.
  • 170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.